Equities research analysts at HC Wainwright lifted their Q1 2025 EPS estimates for Akero Therapeutics in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst E. Arce now ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc.

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against the other biotech stocks. No matter the market environment, you’ll always find ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enro ...

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by ...

In a recent transaction, Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), sold 516 shares of... Andrew Cheng, President and CEO of Akero Therapeutics ...